Moderna Inc (MRNA) stock is lower by -11.31% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives MRNA stock a score of 74 out of a possible 100.
That rank is chiefly influenced by a fundamental score of 94. In addition to the average rating from Wall Street analysts, MRNA stock has a mean target price of $237.31. This means analysts expect the stock to climb 66.79% over the next 12 months. MRNA's rank also includes a long-term technical score of 66. The short-term technical score for MRNA is 61. MRNA has an Overall Score of 74. Find out what this means to you and get the rest of the rankings on MRNA!